Page last updated: 2024-11-13

cd 3254

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CD 3254: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44566110
CHEMBL ID491294
SCHEMBL ID13343636
MeSH IDM0516721

Synonyms (18)

Synonym
cd 3254
(e)-3-[4-hydroxy-3-(3,5,5,8,8-pentamethyl-6, 7-dihydronaphthalen-2-yl)phenyl]prop-2-enoic acid
cd-3254
cd3254
gtpl2810
CHEMBL491294
196961-43-0
(e)-3-[4-hydroxy-3-(1,1,4,4,7-pentamethyltetralin-6-yl)phenyl]prop-2-enoic acid
SCHEMBL13343636
3-[4-hydroxy-3-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)phenyl]-2-propenoic acid
AKOS024457538
J-012733
Q27075803
(e)-3-(4-hydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)phenyl)acrylic acid
(e)-3-[4-hydroxy-3-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)phenyl]prop-2-enoic acid
WHA96143
3-[4-hydroxy-3-(5,6,7,8-tetrahtdro-3,5,5,8,8-pentamethyl-2-naphthalenyl)phenyl]-2-propenoic acid
AKOS040741522
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1069743Agonist activity at recombinant GST-tagged RXRalpha LBD (unknown origin) assessed as induction of biotinylated SRC-1-676-700 coactivator recruitment after 4 hrs by TR-FRET assay (Rvb = 148 +/- 7%)2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids.
AID1069748Antagonist activity at Gal4-fused RARalpha (unknown origin) transfected in HEK293 cells assessed as ATRA-induced transcriptional activity at 4 uM by luciferase/beta-galactosidase reporter gene assay relative to ATRA-treated control2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids.
AID1069750Agonist activity at Gal4-fused RARalpha (unknown origin) transfected in HEK293 cells assessed as induction of transcriptional activity at 4 uM after 6 hrs by luciferase/beta-galactosidase reporter gene assay relative to control2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids.
AID1069749Agonist activity at Gal4-fused RXRalpha (unknown origin) transfected in HEK293 cells assessed as induction of transcriptional activity at 4 uM after 24 hrs by luciferase/beta-galactosidase reporter gene assay relative to control2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids.
AID1525213Binding affinity to recombinant human RXRalpha LBD (592 to 1386 residues) expressed in Escherichia coli BL21 (DE3) by fluorescence quenching assay2019Journal of natural products, 05-24, Volume: 82, Issue:5
Cytotoxic Components from Hypericum elodeoides Targeting RXRα and Inducing HeLa Cell Apoptosis through Caspase-8 Activation and PARP Cleavage.
AID1069744Agonist activity at recombinant GST-tagged RXRalpha LBD (unknown origin) assessed as induction of fluorescein labeled D22 coactivator recruitment after 4 hrs by TR-FRET assay relative to control2014Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4
Inhibition of IκB kinase-β and IκB kinase-α by heterocyclic adamantyl arotinoids.
AID350577Activity at RARalpha/RXRalpha ligand binding domain assessed as stabilization of RXR helix H12 by fluorescence anisotropy in presence of 1 uM coactivator peptide TIF-NR22009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Modulating retinoid X receptor with a series of (E)-3-[4-hydroxy-3-(3-alkoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)phenyl]acrylic acids and their 4-alkoxy isomers.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (25.00)29.6817
2010's4 (50.00)24.3611
2020's2 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]